UCSD launches new clinical trial for breast cancer drug

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

SAN DIEGO — UC San Diego medical researchers said Monday they are recruiting patients for a clinical test of a new antibody designed to be used in tandem with chemotherapy to treat certain breast cancers that cannot be removed surgically.

Researchers plan to recruit up to 15 eligible patients for the trial, in which they will take the drug, called cirmtuzumab, in combination with a chemotherapy medication derived from the Pacific yew tree for six months.

UCSD researchers developed cirmtuzumab along with the California Institute for Regenerative Medicine and UCSD’s Alpha Clinic. Cirmtuzumab targets a protein present in tumors but not in normal adult body tissue, allowing it to target cancer stem cells. The drug was originally meant as a potential treatment for chronic lymphocytic leukemia and is now being tested on other types of cancer.

“Our primary objective, of course, is to determine whether the drug combination is safe and tolerable and to measure its anti-tumor activity,” said Dr. Barbara Parker, professor of medicine, breast oncologist and senior deputy director of cancer medicine at Moores Cancer Center at UCSD. “If it proves safe and shows effectiveness against breast cancer, we can progress to subsequent trials to determine how best to use the drug combination.”

UCSD researchers launched a trial earlier this year to study cirmtuzumab’s effect when paired with a small molecule drug called ibrutinib and are continuing to recruit patients with chronic lymphocytic leukemia and mantle cell lymphoma.

“Cirmtuzumab targets leukemia and cancer stem cells, which are like the seeds of cancer. They are hard to find and difficult to destroy,” said Dr. Thomas Kipps, a professor of medicine and developer or cirmtuzumab. “By blocking signaling pathways that promote cancer growth and survival, cirmtuzumab may have complementary activity with ibrutinib in killing leukemia cells, allowing patients potentially to achieve complete remissions that permit patients to stop therapy altogether.”

New diagnoses of breast cancer in women and men reach almost 270,000 annually, making it the most common form of cancer, and result in an estimated 41,000 deaths every year. Similarly, chronic lymphocytic leukemia is the most common form of blood cancer, with an estimated 21,000 new cases and 4,500 deaths annually.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.